Forward Genetics in Organoid Models
Gastric cancer, cancer of the stomach, is widespread and affects around 3 million people worldwide 1. Due to a lack of clinical signs, gastric cancers are often diagnosed too late for curative treatment, making it the third most deadly type of cancer. Treatment still relies heavily on chemotherapy, as genetic markers for targeted therapy are rare and/or not well characterized. However, genetic markers are especially important for treating relapse patients who developed a resistance to chemotherapeutics (“secondary resistance”).
Our group is using a novel, 3-dimensional tissue culture model, “organoids”, to investigate putative resistance markers in gastric cancers. Organoids have been developed for several human tissues, among them gastric organoids 2. Recent work of our group demonstrated that gastric organoids, similar to cancer in vivo, could develop drug resistances after pretreatment with either chemotherapeutical or targeted drugs.
- Development of a screening set up for gastric cancer organoids to test secondary resistances
- Identification of genetic markers of secondary resistance in culture
- Validation of the role of genetic markers using CRISPR-Cas9 screening
Lab members:
© Marie Brombach
Dr. Jovan Mircetic
Eine verschlüsselte E-Mail über das SecureMail-Portal versenden (nur für TUD-externe Personen).
|
POSITIONS |
|
|---|---|
| since 09/2019 | MSNZ Research group leader at
Biotechnology Center of the TU Dresden (BIOTEC) |
| 2018-2019 |
Postdoc at Medical Systems lab, AG Buchholz, Biotechnology Center of the TU Dresden (BIOTEC) |
| EDUCATION | |
|---|---|
| 2011-2018 | PhD-student at AG Buchholz, Dresden within the DIGS-BB |
| 2005-2010 | Master in Science in molecular biology and physiology, University of Belgrade, Serbia |
| HONORS | |
|---|---|
| 2018 | German Consortium for Translational Cancer Research (DKTK) consumables grant (20.000€) |
| 2018 | PhD thesis “Synthetic biology approach to developing a genetic sensor that targets tumor suppressor deficient cells” defended with summa cum laude |
| 2011-2014 | Fellowship at Dresden International Graduate School for Biomedicine and Bioengineering (DIGS-BB) |
| 2009 | EFG Scholarship and Award |
SELECTED PUBLICATIONS
Mircetic J, Dietrich A, Paszkowski-Rogacz M, Krause M, Buchholz F. Development of a genetic sensor that eliminates p53 deficient cells.Nat Commun. 2017 Nov 13;8(1):1463. PMID: 29133879
Mircetic J, Steinebrünner, I.,..., Buchholz, F. (2017). Purified Cas9 fusion proteins for advanced genome manipulation. Small Meth.1600052.
Gebler, C., Lohoff, T, ... Mircetic, J ....Thiede, C., and Buchholz, F. (2016) Inactivation of cancer mutations utilizing CRISPR/Cas9. J. Natl. Cancer Inst. 109, djw183. PMID: 27576906
for complete publication record see ORCID
Links:
| POSITIONS AND EDUCATION | |
|---|---|
| since 09/2019 | Leading Clinical Scientist at MSNZ group "Resistance marker in gastric cancer" |
| 10/2011-12/2015 | Medical doctorate in the laboratory of Prof. Dr. Jürgen Weitz, Heidelberg and Dresden |
| 03/2003-12/2009 | Medical Studies, University of Chile, Santiago, Chile |
| CLINICAL TRAINING | |
|---|---|
| since 2016 | Resident at the VTG at Uiniversitätsklinikum Dresden |
| 01/2010-09/2011 | General Practioner, Santiago, Chile |
| HONORS | |
|---|---|
| 2011 |
Becas Chile-Scholarship |
SELECTED PUBLICATIONS
Branchi V, García SA, …., Schölch S. Prognostic value of DLGAP5 in colorectal cancer. (2019) Int J Colorectal Dis. PMID: 31286215
García SA, Weitz J, Schölch S. Circulating Tumor Cells.Methods Mol Biol. 2018;1692:213-219.
Kochall S, Thepkaysone ML, García SA, Betzler AM, Weitz J, Reissfelder C, Schölch S. Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer. J Vis Exp. 2017 Jul 18;(125).
García SA, Swiersy A,..., Kahlert C, ..., Weitz J, Schölch S.(2016) LDB1 overexpression is a negative prognostic factor in colorectal cancer. Oncotarget. PMID: 27713177
for complete publication record see ORCID
LINKS
© Marie Brombach
Marie-Christin Mehnert M.Sc.
Eine verschlüsselte E-Mail über das SecureMail-Portal versenden (nur für TUD-externe Personen).
© Marie Brombach
Julia Paditz M.Sc.
Eine verschlüsselte E-Mail über das SecureMail-Portal versenden (nur für TUD-externe Personen).
Moustafa Abohawya
Eine verschlüsselte E-Mail über das SecureMail-Portal versenden (nur für TUD-externe Personen).
Selected publications:
Mircetic J, Dietrich A, Paszkowski-Rogacz M, Krause M, Buchholz F. Development of a genetic sensor that eliminates p53 deficient cells. Nat Commun. 2017 Nov 13;8(1):1463.
García SA, Weitz J, Schölch S. Circulating Tumor Cells.Methods Mol Biol. 2018;1692:213-219.
Kochall S, Thepkaysone ML, García SA, Betzler AM, Weitz J, Reissfelder C, Schölch S. Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer. J Vis Exp. 2017 Jul 18;(125).
Lab activities:
Contact:
© Marie Brombach
Tandemlab Mircetic/Garcia
Eine verschlüsselte E-Mail über das SecureMail-Portal versenden (nur für TUD-externe Personen).